Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

被引：0

作者：

Mats Någård

Mei-Lin Ah-See

Karen So

Marit Vermunt

Fiona Thistlethwaite

Mariette Labots

Patricia Roxburgh

Alain Ravaud

Mario Campone

Liselot Valkenburg-van Iersel

Lone Ottesen

Yan Li

Ganesh Mugundu

机构：

[1] R&D Clinical Pharmacology and Safety Sciences,Clinical Pharmacology and Quantitative Pharmacology

[2] AstraZeneca,Late Stage Development, Oncology R&D

[3] AstraZeneca,Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D

[4] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences

[5] The Christie NHS Foundation Trust and University of Manchester,undefined

[6] Cancer Center Amsterdam,undefined

[7] Amsterdam UMC,undefined

[8] Beaston West of Scotland Cancer Centre and University of Glasgow,undefined

[9] Bordeaux University Hospital,undefined

[10] ICO – Site René,undefined

[11] Maastricht University Medical Centre,undefined

[12] AstraZeneca,undefined

[13] AstraZeneca,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2020年 / 86卷

关键词：

Adavosertib; Food effect; Pharmacokinetics; Oncology; WEE1;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：97 / 108

页数：11

共 50 条

[1] Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
Nagard, Mats
Ah-See, Mei-Lin
So, Karen
Vermunt, Marit
Thistlethwaite, Fiona
Labots, Mariette
Roxburgh, Patricia
Ravaud, Alain
Campone, Mario
Valkenburg-van Iersel, Liselot
Ottesen, Lone
Li, Yan
Mugundu, Ganesh
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 97 - 108
[2] Effect of food on the pharmacokinetics of the wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
Nagard, M.
So, K.
Ah-See, M. L.
Vermunt, M.
Thistlethwaite, F.
Labots, M.
Roxburgh, P.
Ravaud, A.
Campone, M.
Valkenburg-van Iersel, L.
Ottesen, L.
Mugundu, G.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : E12 - E12
[3] The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase lb study
Bang, Yung-Jue
De Souza, Paul
Kim, Sang-We
Lickliter, Jason
Naito, Yoichi
Park, Keunchil
Kumar, Sanjeev
Mugundu, Ganesh M.
Kato, Hidenori
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[4] A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
Todd M. Bauer
Kathleen N. Moore
Janet S. Rader
Fiona Simpkins
Alain C. Mita
J. Thaddeus Beck
Lowell Hart
Quincy Chu
Amit Oza
Anna V. Tinker
Esteban Rodrigo Imedio
Sanjeev Kumar
Ganesh Mugundu
Suzanne Jenkins
Juliann Chmielecki
Suzanne Jones
David Spigel
Siqing Fu
Targeted Oncology, 2023, 18 : 517 - 530
[5] A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
Bauer, Todd M.
Moore, Kathleen N.
Rader, Janet S.
Simpkins, Fiona
Mita, Alain C.
Beck, J. Thaddeus
Hart, Lowell
Chu, Quincy
Oza, Amit
Tinker, Anna V.
Imedio, Esteban Rodrigo
Kumar, Sanjeev
Mugundu, Ganesh
Jenkins, Suzanne
Chmielecki, Juliann
Jones, Suzanne
Spigel, David
Fu, Siqing
TARGETED ONCOLOGY, 2023, 18 (04) : 517 - 530
[6] Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Takebe, Naoko
Naqash, Abdul Rafeh
Coyne, Geraldine O'Sullivan
Kummar, Shivaani
Do, Khanh
Bruns, Ashley
Juwara, Lamin
Zlott, Jennifer
Rubinstein, Larry
Piekarz, Richard
Sharon, Elad
Streicher, Howard
Mittra, Arjun
Miller, Sarah B.
Ji, Jiuping
Wilsker, Deborah
Kinders, Robert J.
Parchment, Ralph E.
Chen, Li
Chang, Ting-Chia
Das, Biswajit
Mugundu, Ganesh
Doroshow, James H.
Chen, Alice P.
CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3834 - 3844
[7] A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma
Liu, J. F.
Tayob, N.
Campos, S. M.
Wright, A. A.
Krasner, C.
Schumer, S.
Horowitz, N. S.
Veneris, J. L. T.
Xiong, N.
West, G.
Quinn, R.
Matulonis, U. A.
Konstantinopoulos, P. A.
GYNECOLOGIC ONCOLOGY, 2020, 159 : 5 - 5
[8] Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
Cuneo, Kyle C.
Morgan, Meredith A.
Sahai, Vaibhav
Schipper, Matthew J.
Parsels, Leslie A.
Parsels, Joshua D.
Devasia, Theresa
Al-Hawaray, Mahmoud
Cho, Clifford S.
Nathan, Hari
Maybaum, Jonathan
Zalupski, Mark M.
Lawrence, Theodore S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) : 2643 - +
[9] Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors
Do, Khanh Tu
Wilsker, Deborah
Balasubramanian, Priya
Zlott, Jennifer
Jeong, Woondong
Lawrence, Scott M.
Kinders, Robert J.
Collins, Jerry
Chen, Alice P.
Doroshow, James H.
Kummar, Shivaani
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[10] A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma.
Liu, Joyce F.
Xiong, Niya
Campos, Susana M.
Wright, Alexi A.
Krasner, Carolyn N.
Schumer, Susan T.
Horowitz, Neil S.
Veneris, Jennifer Taylor
Tayob, Nabihah
Morrissey, Stephanie
West, Gabriela
Quinn, Roxanne
Matulonis, Ursula A.
Konstantinopoulos, Panagiotis A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →